Top Markets
Coin of the day
Brickell Biotech, Inc. Brickell Biotech, Inc.

Brickell Biotech, Inc.

BBI
Pozycja w akcjach #40377
Brickell Biotech, Inc. is a pharmaceutical company currently in the clinical... Brickell Biotech, Inc. is a pharmaceutical company currently in the clinical development phase, dedicated to creating prescription medicines for various debilitating conditions, including autoimmune and inflammatory disorders, primarily within the United States. Its product pipeline includes sofpironium bromide, which has successfully finished Phase III clinical trials for treating excessive underarm sweating (primary axillary hyperhidrosis). Other notable candidates are BBI-02, an oral DYRK1A inhibitor targeting autoimmune and inflammatory diseases, and BBI-10, a covalent stimulator of interferon genes (STING) inhibitor, being explored for autoinflammatory and rare genetic illnesses. The company is also advancing next-generation kinase inhibitors. Brickell Biotech collaborates with several partners, such as Carna Biosciences, Inc., Voronoi Inc., Bodor Laboratories, Inc. and Dr. Nicholas S. Bodor, and AnGes, Inc. Established in 2009, its main office is located in Boulder, Colorado.
Cena akcji
$2.35
Ostatnia synchronizacja: 2022-09-07
Kapitalizacja rynkowa
$162.94K
Zmiana (1 dzień)
2.17%
Zmiana (1 rok)
0.00%
Kraj
US
Handel Brickell Biotech, Inc. (BBI)

Kategoria

Historia ceny akcji dla Brickell Biotech, Inc. (BBI)
Najwyższa cena zamknięcia: $2.40 dnia 2022-09-01

Najniższa cena zamknięcia: $194.34 dnia 2019-09-01
Historia cen akcji firmy Brickell Biotech, Inc. od 2019 do 2026
Roczna wydajność ceny akcji
Rok Wydajność
2022 -80.40%
2021 -62.42%
2020 -56.44%
2019 0.00%
Cena akcji podobnych firm lub konkurencji
Firma Cena akcji Zmiana 1r% Kraj
$517.18 32.51%
US
$857.76 31.47%
NL
$744.96 9.07%
CH
$1.08K -5.43%
KR
$259.89 14.81%
BE